Patents by Inventor Sumiti Jain

Sumiti Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TARGETED DISRUPTION OF T CELL AND/OR HLA RECEPTORS
    Publication number: 20230295563
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Application
    Filed: October 21, 2022
    Publication date: September 21, 2023
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • CHIMERIC STIMULATORY RECEPTORS AND METHODS OF USE IN T CELL ACTIVATION AND DIFFERENTIATION
    Publication number: 20230121433
    Abstract: Disclosed are chimeric stimulatory receptors (CSRs), cell compositions comprising CSRs, methods of making and methods of using same for the treatment of a disease or disorder in a subject.
    Type: Application
    Filed: March 11, 2021
    Publication date: April 20, 2023
    Inventors: Devon SHEDLOCK, Sumiti JAIN
  • Targeted disruption of T cell and/or HLA receptors
    Patent number: 11512287
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: November 29, 2022
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang
  • CHIMERIC ANTIGEN RECEPTOR MEDIATED CELL TARGETING
    Publication number: 20190048060
    Abstract: Disclosed herein are methods and compositions for engineering cells to express a CAR where the cells also have inactivated TCR, HPRT, PD1, CISH and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Application
    Filed: August 8, 2018
    Publication date: February 14, 2019
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, Andreas Reik, Lynn N. Truong
  • TARGETED DISRUPTION OF T CELL AND/OR HLA RECEPTORS
    Publication number: 20180362926
    Abstract: Disclosed herein are methods and compositions for inactivating TCR and/or HLA genes, using engineered nucleases comprising at least one DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Anthony Conway, Sumiti Jain, Gary K. Lee, David Paschon, Edward J. Rebar, Lei Zhang